Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Geary

Showing results (71-80 of 152) with videos related to

Pageof 16
Sort By:
Pediatric Neurosurgery|August 7, 1998
Endoscopic third ventriculocisternostomy: MR assessment of patency with 2-D cine phase-contrast versus T2-weighted fast spin echo techniqueN J Fischbein, S F Ciricillo, R M Barr, et al.
Nucleic Acid Therapeutics|June 27, 2020
Treatment with Volanesorsen, a 2'-O-Methoxyethyl-Modified Antisense Oligonucleotide Targeting <i>APOC3</i> mRNA, Does Not Affect the QTc Interval in Healthy VolunteersLynnetta M Watts, Ewa Karwatowska-Prokopczuk, Eunju Hurh, et al.
European Heart Journal|July 23, 2019
N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levelsVeronica J Alexander, Shuting Xia, Eunju Hurh, et al.
Nucleic Acid Therapeutics|January 16, 2024
Safety and Tolerability of GalNAc<sub>3</sub>-Conjugated Antisense Drugs Compared to the Same-Sequence 2'-<i>O</i>-Methoxyethyl-Modified Antisense Drugs: Results from an Integrated Assessment of Phase 1 Clinical Trial DataBrenda F Baker, Shuting Xia, Wesley Partridge, et al.
Antisense & Nucleic Acid Drug Development|April 15, 2003
Prediction of clinical responses in a simulated phase III trial of Crohn's patients administered the antisense phosphorothioate oligonucleotide ISIS 2302: comparison of proposed dosing regimensRosie Z Yu, John Q Su, John S Grundy, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 22, 2001
Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in ratsR S Geary, O Khatsenko, K Bunker, et al.
Nucleic Acid Therapeutics|August 6, 2014
Mechanism of alternative complement pathway dysregulation by a phosphorothioate oligonucleotide in monkey and human serumScott P Henry, Mark A Jagels, Tony E Hugli, et al.
Health & Place|February 13, 2026
Residential green and blue space effects on newborn health: findings from a retrospective longitudinal study in WalesRukun K S Khalaf, Roberto Villegas-Diaz, Olly Butters, et al.
JACC. Basic to Translational Science|July 5, 2021
Antisense Inhibition of Angiotensinogen With IONIS-AGT-L<sub>Rx</sub>: Results of Phase 1 and Phase 2 StudiesErin S Morgan, Yvonne Tami, Kuolung Hu, et al.
Nucleic Acid Therapeutics|December 21, 2018
Integrated Assessment of the Clinical Performance of GalNAc<sub>3</sub>-Conjugated 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer ExperienceStanley T Crooke, Brenda F Baker, Shuting Xia, et al.
Pageof 16

Showing results (71-80 of 152) with videos related to

Sort By:
Pageof 16
Pediatric Neurosurgery|August 7, 1998
Endoscopic third ventriculocisternostomy: MR assessment of patency with 2-D cine phase-contrast versus T2-weighted fast spin echo techniqueN J Fischbein, S F Ciricillo, R M Barr, et al.
Nucleic Acid Therapeutics|June 27, 2020
Treatment with Volanesorsen, a 2'-O-Methoxyethyl-Modified Antisense Oligonucleotide Targeting <i>APOC3</i> mRNA, Does Not Affect the QTc Interval in Healthy VolunteersLynnetta M Watts, Ewa Karwatowska-Prokopczuk, Eunju Hurh, et al.
European Heart Journal|July 23, 2019
N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levelsVeronica J Alexander, Shuting Xia, Eunju Hurh, et al.
Nucleic Acid Therapeutics|January 16, 2024
Safety and Tolerability of GalNAc<sub>3</sub>-Conjugated Antisense Drugs Compared to the Same-Sequence 2'-<i>O</i>-Methoxyethyl-Modified Antisense Drugs: Results from an Integrated Assessment of Phase 1 Clinical Trial DataBrenda F Baker, Shuting Xia, Wesley Partridge, et al.
Antisense & Nucleic Acid Drug Development|April 15, 2003
Prediction of clinical responses in a simulated phase III trial of Crohn's patients administered the antisense phosphorothioate oligonucleotide ISIS 2302: comparison of proposed dosing regimensRosie Z Yu, John Q Su, John S Grundy, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 22, 2001
Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in ratsR S Geary, O Khatsenko, K Bunker, et al.
Nucleic Acid Therapeutics|August 6, 2014
Mechanism of alternative complement pathway dysregulation by a phosphorothioate oligonucleotide in monkey and human serumScott P Henry, Mark A Jagels, Tony E Hugli, et al.
Health & Place|February 13, 2026
Residential green and blue space effects on newborn health: findings from a retrospective longitudinal study in WalesRukun K S Khalaf, Roberto Villegas-Diaz, Olly Butters, et al.
JACC. Basic to Translational Science|July 5, 2021
Antisense Inhibition of Angiotensinogen With IONIS-AGT-L<sub>Rx</sub>: Results of Phase 1 and Phase 2 StudiesErin S Morgan, Yvonne Tami, Kuolung Hu, et al.
Nucleic Acid Therapeutics|December 21, 2018
Integrated Assessment of the Clinical Performance of GalNAc<sub>3</sub>-Conjugated 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer ExperienceStanley T Crooke, Brenda F Baker, Shuting Xia, et al.
Pageof 16